Stock analysts at Credit Suisse Group AG began coverage on shares of Ra Pharmaceuticals Inc (NASDAQ:RARX) in a note issued to investors on Monday. The firm set an “outperform” rating and a $19.00 price target on the stock. Credit Suisse Group AG’s price objective would indicate a potential upside of 46.15% from the company’s current price.

A number of other research analysts also recently weighed in on RARX. SunTrust Banks Inc. started coverage on shares of Ra Pharmaceuticals in a research report on Monday. They set a “buy” rating and a $32.00 target price for the company. Jefferies Group started coverage on shares of Ra Pharmaceuticals in a report on Monday. They issued a “buy” rating for the company.

Ra Pharmaceuticals (NASDAQ:RARX) opened at 13.00 on Monday. The firm’s market capitalization is $7.20 million. Ra Pharmaceuticals has a one year low of $12.33 and a one year high of $14.86. The stock’s 50 day moving average is $13.17 and its 200 day moving average is $13.17.

In other Ra Pharmaceuticals news, major shareholder Harry R. Weller acquired 338,462 shares of the business’s stock in a transaction that occurred on Monday, October 31st. The stock was bought at an average cost of $13.00 per share, with a total value of $4,400,006.00. The purchase was disclosed in a document filed with the SEC, which is available at the SEC website. Also, Director Rajeev M. Shah acquired 161,538 shares of the business’s stock in a transaction that occurred on Monday, October 31st. The stock was acquired at an average cost of $13.00 per share, with a total value of $2,099,994.00. The disclosure for this purchase can be found here.

WARNING: “Credit Suisse Group AG Initiates Coverage on Ra Pharmaceuticals Inc (RARX)” was reported by The Cerbat Gem and is the propert of of The Cerbat Gem. If you are viewing this piece of content on another site, it was copied illegally and reposted in violation of international trademark and copyright legislation. The correct version of this piece of content can be accessed at https://www.thecerbatgem.com/2016/11/23/credit-suisse-group-ag-initiates-coverage-on-ra-pharmaceuticals-inc-rarx.html.

About Ra Pharmaceuticals

Ra Pharmaceuticals, Inc is a United States-based clinical-stage biopharmaceutical company. The Company focuses on the development of therapeutics for diseases of complement dysregulation and a range of orphan indications. It utilizes small molecules and peptide approaches to address pathological targets in the complement cascade.

5 Day Chart for NASDAQ:RARX

Receive News & Stock Ratings for Ra Pharmaceuticals Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Ra Pharmaceuticals Inc and related stocks with our FREE daily email newsletter.